8RPB

Structure of S79 Fab in complex with IgV domain of human PD-L1

8RPB の概要

• エントリーDOI: 10.2210/pdb8rpb/pdb
• 分子名称: heavy chain of S79 fab, light chain of S79 fab, Programmed cell death 1 ligand 1, ... (7 entities in total)
• 機能のキーワード: immune system, fab
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 61617.03

構造登録者

Svensson, A.,Kelpsas, V.,Laursen, M.,Rose, N. (登録日: 2024-01-15, 公開日: 2024-06-19, 最終更新日: 2024-10-16)

主引用文献

Malinge, P.,Chauchet, X.,Bourguignon, J.,Bosson, N.,Calloud, S.,Bautzova, T.,Borlet, M.,Laursen, M.,Kelpsas, V.,Rose, N.,Gueneau, F.,Ravn, U.,Magistrelli, G.,Fischer, N.
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.
Mabs, 16:2362432-2362432, 2024

PubMed Abstract: In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format in which the light chain (LC) drives antigen binding and specificity. To better understand epitope-paratope interactions in this context, we determined the X-ray crystallographic structures of an antigen binding fragment (Fab) in complex with human CD47 and another Fab in complex with human PD-L1. These Fabs contain a κ-LC and a λ-LC, respectively, which are paired with an identical heavy chain (HC). The structural analysis of these complexes revealed the dominant contribution of the LCs to antigen binding, but also that the common HC provides some contacts in both CD47 and PD-L1 Fab complexes. The anti-CD47 Fab was affinity optimized by diversifying complementary-determining regions of the LC followed by phage display selections. Using homology modeling, the contributions of the amino acid modification to the affinity increase were analyzed. Our results demonstrate that, despite a less prominent role in natural antibodies, the LC can mediate high affinity binding to different antigens and neutralize their biological function. Importantly, Fabs containing a common variable heavy (VH) domain enable the generation of bispecific antibodies retaining a truly native structure, maximizing their therapeutic potential.

PubMed: 38849989
DOI: 10.1080/19420862.2024.2362432

実験手法

X-RAY DIFFRACTION (2.794 Å)